Compare NBTB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | IMNM |
|---|---|---|
| Founded | 1856 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | NBTB | IMNM |
|---|---|---|
| Price | $42.63 | $21.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $51.00 | $31.44 |
| AVG Volume (30 Days) | 227.2K | ★ 2.9M |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 5.89 | N/A |
| EPS | ★ 3.02 | N/A |
| Revenue | ★ $629,728,000.00 | $9,679,000.00 |
| Revenue This Year | $27.08 | N/A |
| Revenue Next Year | $9.17 | $11.53 |
| P/E Ratio | $14.14 | ★ N/A |
| Revenue Growth | ★ 16.88 | N/A |
| 52 Week Low | $37.31 | $5.15 |
| 52 Week High | $49.43 | $25.30 |
| Indicator | NBTB | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 58.53 |
| Support Level | $42.31 | $21.33 |
| Resistance Level | $42.91 | $22.57 |
| Average True Range (ATR) | 0.97 | 1.44 |
| MACD | -0.20 | 0.01 |
| Stochastic Oscillator | 30.97 | 48.23 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.